Dova Pharmaceuticals announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, adopted a “positive” opinion for the use of Doptelet for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. Read more at: https://thefly.com/landingPageNews.php?id=2898923
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.